DPHA — Disruptive Pharma AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK21.98m
- -SEK12.12m
Brief: Guard Therapeutics Receives Regulatory EU Approvals
Brief: Guard Therapeutics Carries Out Directed Share Issue
Brief: Guard Therapeutics Q1 Pre-Tax Loss Narrows To SEK 14.5 Mln
Brief: Guard Therapeutics Q4 Operating Loss Narrows To SEK 15.3 Mln
Brief: Guard Therapeutics RMC-035 Development Plan Receives Positive Feedback From FDA
Brief: Guard Therapeutics Q3 Pre-Tax Loss Narrows To SEK 23.3 Mln
Brief: Guard Therapeutics Reports Efficacy Of Rmc-035 In Phase 2 (Akita) And Advances Clinical Development Program
Brief: Guard Therapeutics International Q2 Loss Widens To SEK 33.0 Mln
Brief: Guard Therapeutics Says Study On RMC-035 Confirms Positive Data
Brief: Guard Therapeutics Q1 Loss Widens To SEK 39.9 Mln
Brief: Guard Therapeutics Closes Phase 2 Clinical Trial
Brief: Guard Therapeutics Announces Positive Results Of Phase 1b Trial
Brief: Guard Therapeutics International Q4 Loss After Tax Widens To SEK 40.5 Million
Brief: Results From Guard Therapeutics' Phase 1B Study In Cardiac Surgery Published
Brief: Guard Therapeutics Receives Patent Approval For RMC-035 In China
Brief: Guard Therapeutics International Q3 Net Loss Narrows To SEK 32.4 Mln
Brief: Guard Therapeutics To Carry Out New Share Issue Of SEK 120 Million
Brief: Guard Therapeutics Granted FDA Fast Track Designation For Rmc-035
Brief: Guard Therapeutics Receives IND Approval From FDA For RMC-035